Drugs versus surgery for early kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares two approaches for people with a certain type of early kidney cancer: taking two medications (anlotinib and benmelstobart) instead of having surgery to remove the tumor. The goal is to see if the medications work as well as or better than surgery at controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your kidney cancer is newly diagnosed and at an early stage (cT1bN0M0), meaning it has not spread to lymph nodes or other organs.
- You are otherwise healthy enough that you can do your usual activities (ECOG 0 or 1).
- You have not had any prior treatment for kidney cancer, such as targeted therapy, immunotherapy, or hormone therapy.
- You are not planning to have surgery on both kidneys or have multiple tumors in one kidney.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial compares two new treatment options for advanced kidney cancer (clear cell type) that has worsened after immunotherapy. One group gets two oral drugs (vorolanib and everolimus) together; the other gets a standard targeted therapy (sunitinib).
This trial tests whether giving an immunotherapy drug (PD-L1 inhibitor) and an oral medication (anlotinib) before surgery can help shrink complex kidney tumors so that surgeons can remove only part of the kidney, preserving more kidney function. It may help you avoid losing your whole kidney.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests a combination of precise radiation (SBRT) plus two drugs (anlotinib and bimepolizumab) to see if it helps control advanced kidney cancer. The goal is to shrink tumors and slow the cancer's growth.
This trial tests if taking two drugs, belzutifan and pembrolizumab, before surgery can help shrink high-risk kidney cancer tumors and improve outcomes. It may be an option for people with locally advanced clear cell kidney cancer who are scheduled for nephrectomy.
Hear when a new Renal Cell Carcinoma (RCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.